ARTICLE | Company News
Aposense, Teva deal
June 21, 2010 7:00 AM UTC
Teva plans to invest up to an additional $9 million in its September 2005 deal with Aposense to co-develop therapeutics comprised of an Aposense probe conjugated to generic cytotoxic agents to treat c...